CLASS ACTION UPDATE for AMPE, NVRO and LCI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
  

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE)
Class Period: December 14, 2017 - August 7, 2018
Lead Plaintiff Deadline: October 24, 2018
Join the action: http://www.zlk.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3

About the lawsuit: During the class period, Ampio Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times.

To learn more about the Ampio Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.
  

Nevro Corp. (NYSE: NVRO)
Class Period: January 8, 2018 - July 12, 2018
Lead Plaintiff Deadline: October 22, 2018
Join the action: http://www.zlk.com/pslra-1/nevro-corp-loss-form?wire=3

About the lawsuit: Nevro Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company's Senza I and Senza II systems; (2) as a result, Nevro's Senza I and Senza II systems were not "novel" or "proprietary;" (3) these practices caused Nevro to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) as a result, Nevro's U.S. sales growth was not sustainable; and (5) consequently, defendants' statements about Nevro's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the Nevro Corp. class action contact jlevi@levikorsinsky.com.
  

Lannett Company, Inc. (NYSE: LCI)
Class Period: February 7, 2018 - August 17, 2018
Lead Plaintiff Deadline: October 26, 2018
Join the action: http://www.zlk.com/pslra-1/lannett-company-inc-loss-form?wire=3

About the lawsuit: Lannett Company, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) Lannett faced a substantial risk of the loss of its exclusivity agreement with Jerome Stevens Pharmaceuticals; (2) accordingly, Lannett’s reported revenues were unsustainable; and (3) as a result, Lannett’s public statements were materially false and misleading at all relevant times.

To learn more about the Lannett Company, Inc. class action contact jlevi@levikorsinsky.com.
  

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.


CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com